Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies

J F Falantes; E Carrillo; F Márquez; M Carmona; I Espigado

doi:10.1016/j.transproceed.2010.05.045

Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies

Transplant Proc. 2010 Oct;42(8):3225-7. doi: 10.1016/j.transproceed.2010.05.045.

Authors

J F Falantes¹, E Carrillo, F Márquez, M Carmona, I Espigado

Affiliation

¹ Hematology, Bone Marrow Transplant Unit, Hospital Universitario Virgen del Rocío, Seville, Spain. josef.falantes.sspa@juntadeandalucia.es

PMID: 20970659
DOI: 10.1016/j.transproceed.2010.05.045

Abstract

Prognosis of patients relapsing after stem cell transplantation (SCT) is poor if no further treatment is given. A second SCT is a limited option in these high-risk patients. We retrospectively analyzed the outcomes of second SCT in acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia after a first SCT. Twenty-five of 30 patients received second allogeneic SCT. Variables related to survival were disease status before second allogeneic SCT and time interval between transplants more than 1 year (P<.01 and P<.02 in multivariate analysis). Treatment-related mortality was 33% with no impact of the conditioning regimen on overall survival. Second allogeneic SCT in selected patients may be an option in this group with a poor outcome.

MeSH terms

Cohort Studies
Hematologic Neoplasms / surgery*
Hematopoietic Stem Cell Transplantation*
Humans
Prognosis
Recurrence
Survival Rate